Dr. REX MOWAT, MD
Claim this profileToledo Clinic Cancer Centers-Toledo
About REX MOWAT, MD
Education:
- Earned an MD (Doctor of Medicine).
Experience:
- Currently a practicing physician at the Toledo Clinic Cancer Center with a specialization in oncology.
- Collaborates with the Barbara Ann Karmanos Cancer Institute to enhance access to advanced cancer care, clinical trials, and precision medicine in Northwest Ohio.
Area of expertise
Breast Cancer
REX MOWAT, MD has run 16 trials for Breast Cancer. Some of their research focus areas include:
Cancer
REX MOWAT, MD has run 15 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
Toledo Clinic Cancer Centers-Toledo
Hickman Cancer Center
Clinical Trials REX MOWAT, MD is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to the effect of modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) with or without nivolumab for the treatment of patients with advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, or gastric adenocarcinoma. The usual approach for patients who are not in a study is treatment with FOLFOX with some receiving an immunotherapy drug, either nivolumab or pembrolizumab, in addition to FOLFOX chemotherapy. The usual approach is defined as care most people get for cancer in the stomach, esophagus, or gastroesophageal junction. Fluorouracil is in a class of medications called antimetabolites. It stops cells from making DNA and may kill tumor cells. Leucovorin in a class of medications called folic acid analogs. When used with fluorouracil it enhances the effects of this chemotherapy drug. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and DNA repair, and may kill cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Some patients on this trial will receive nivolumab, in addition to mFOLFOX or mFOLFIRINOX chemotherapy. mFOLFIRINOX with or without nivolumab may be more effective than mFOLFOX with or without nivolumab by shrinking the tumor in patients with advanced, unresectable, or metastatic HER2-negative esophageal, gastroesophageal junction, or gastric adenocarcinoma.
Recruiting
2 awards
Phase 3
2 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
More about REX MOWAT, MD
Clinical Trial Related
3 years of experience running clinical trials · Led 79 trials as a Principal Investigator · 17 Active Clinical Trials
Treatments REX MOWAT, MD has experience with
- Pembrolizumab
- Nivolumab
- Carboplatin
- Fluorouracil
- Paclitaxel
- Ipilimumab
Breakdown of trials REX MOWAT, MD has run
Breast Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does REX MOWAT, MD specialize in?
REX MOWAT, MD focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is REX MOWAT, MD currently recruiting for clinical trials?
Yes, REX MOWAT, MD is currently recruiting for 17 clinical trials in Toledo Ohio. If you're interested in participating, you should apply.
Are there any treatments that REX MOWAT, MD has studied deeply?
Yes, REX MOWAT, MD has studied treatments such as Pembrolizumab, Nivolumab, Carboplatin.
What is the best way to schedule an appointment with REX MOWAT, MD?
Apply for one of the trials that REX MOWAT, MD is conducting.
What is the office address of REX MOWAT, MD?
The office of REX MOWAT, MD is located at: Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio 43623 United States. This is the address for their practice at the Toledo Clinic Cancer Centers-Toledo.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.